Swiss Biotechnology Company Anokion SA Achieves Major Acquisition and Funding, Providing Runway for Multiple Emerging Autoimmune Therapies

Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced the acquisition of Kanyos Bio, Inc. and the completion of a $40 million Series B financing. Anokion has come a long way, according to...

Pin It on Pinterest